BioSpace News Archive

Drug Development

MYR Pharma Completes Clinical Trial of Myrcludex B in Chronic Hepatitis Delta

Myrcludex B is tested in the treatment of HDV - the most severe form of viral hepatitis without current satisfactory treatment options 120 subjects were enrolled into MYR 202, making it the world’s largest HDV clinical study

March 12, 2018
·
1 min read
Business

Bovie Medical Corporation Reports Fourth Quarter and Full Year 2017 Financial Results; Provides Fiscal Year 2018 Financial Outlook

Bovie Medical Corporation reported financial results for its fourth quarter and full year ended December 31, 2017.

March 12, 2018
·
7 min read
Business

Akebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results

Akebia Therapeutics, Inc. announced financial results for the fourth quarter and full year ended December 31, 2017.

March 12, 2018
·
6 min read
Business

Illumina Names Dr. Phil Febbo Chief Medical Officer

Illumina, Inc. announced the appointment of Dr. Phil Febbo, a leading physician scientist, as Chief Medical Officer (CMO), starting March 26, 2018.

March 12, 2018
·
2 min read
Business

Enzo Biochem Reports Second Quarter and First Half Results

Enzo Biochem (NYSE:ENZ) today announced results for the fiscal quarter and six months ended January 31, 2018.

March 12, 2018
·
8 min read
Business

Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)

Advaxis, Inc. announces financial results for the three months ended January 31, 2018 and provides a business update.

March 12, 2018
·
6 min read
Drug Development

Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of GI Cancer Trial

The Guardant360® assay will be used to launch a new arm of a nationwide trial run by SCRUM-Japan GI-SCREEN, organized by the National Cancer Center Hospital East (NCCE), Kashiwa, Japan.

March 12, 2018
·
1 min read
Drug Development

Precision Neuroscience Company Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883

The compound is a selective first-in-class positive allosteric modulator of the small conductance calcium-activated potassium (SK) channel.

March 12, 2018
·
3 min read
Deals

Orexigen Therapeutics, Inc. Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.S. Bankruptcy Code

Orexigen Therapeutics, Inc. announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.

March 12, 2018
·
10 min read
Business

IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer

IO Biotech announces it has entered into a collaborative agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), through a subsidiary, focused on the clinical evaluation of IO102 with KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer (NSCLC).

March 12, 2018
·
1 min read